首页> 外文期刊>International journal of immunopathology and pharmacology. >The Combination of Immunosuppressive Drugs with 8-Methoxypsoralen and Ultraviolet a Light Modulates the Myeloid-Derived Dendritic Cell Function
【24h】

The Combination of Immunosuppressive Drugs with 8-Methoxypsoralen and Ultraviolet a Light Modulates the Myeloid-Derived Dendritic Cell Function

机译:免疫抑制药物与8-甲氧基补骨脂素和紫外线的组合调节髓样来源的树突状细胞的功能。

获取原文
       

摘要

The functional properties of myeloid dendritic cells (DCs) differ, depending on microenvironmental factors as well as on their stage of maturation. The main approaches for the selective enhancement of the tolerogenic properties of DCs include the induction of a pharmacological arrest of the DCs maturation and the genetical engineering of DCs expressing immunosuppressive molecules. Several immunosuppressive/anti-inflammatory agents have been discovered that potentially inhibit DC maturation and immunogenicity. Photopheresis (ECP) is an immunomodulatory therapy in which leucocytes are exposed to 8-methoxypsoralen (8-MOP) and ultraviolet (UV) A radiation (PUVA). The combination of ECP with immunosuppressive agents has demonstrated efficacy in the management of transplanted patients by reducing either the incidence of organ rejection or the pharmacological toxicity. In particular, we have observed in hepatitis C virus (HCV)-positive patients that the same combination has reduced the immunosuppressive burden and improved sustainability and efficacy of pre-emptive antiviral therapy after liver transplantation. Therefore, in our work we investigated the in vitro effects of PUVA, combined with immunosuppressive drugs (IDs), on both in vitro human DC generation and maturation, in order to contribute to understanding the immunological mechanisms underlying this pharmacological combination. Monocyte PUVA-treatment was performed by using an in vitro experimental protocol that we previously described. PUVA-treated or -untreated highly purified CD14+ cells were incubated with the association of the immunosuppressive drugs, used in the management of liver transplantation, at two different concentrations, in the presence of IL-4 and GM-CSF. The treatment with IDs at the highest concentration (corresponding to that used in clinical practice), alone or in association with PUVA, induced an immunosuppressive effect, by impairing both DC generation and maturation. Neither immunosuppressive drugs at the lowest concentration nor their combination with PUVA affected myeloid DC generation, but modified DC functions, strengthening the induction of a tolerogenic pattern. As this ID concentration was arbitrarily chosen, further experiments could highlight whether lower concentrations than those used in clinical practice would elicit the same effect on DCs and potentially improve their functional properties. This work describes an original experimental approach exploring the in vitro mechanism of action of the combined procedure of PUVA with immunosuppressive drugs, used in liver transplantation, on DCs generation and function. Our results contribute to the knowledge of the mechanisms of action of this combined procedure on DCs, suggesting useful therapeutic implications for the in vivo therapy.
机译:骨髓树突状细胞(DCs)的功能特性有所不同,具体取决于微环境因素及其成熟阶段。选择性增强DC的致耐受性的主要方法包括诱导DC成熟的药理学抑制和表达免疫抑制分子的DC的基因工程。已经发现了几种潜在地抑制DC成熟和免疫原性的免疫抑制/抗炎剂。光电穿刺术(ECP)是一种免疫调节疗法,其中白细胞暴露于8-甲氧基补骨脂素(8-MOP)和紫外线(UV)A辐射(PUVA)。通过减少器官排斥的发生率或药理毒性,ECP与免疫抑制剂的组合已显示出对移植患者的治疗效果。特别是,我们在丙型肝炎病毒(HCV)阳性患者中观察到,相同的组合降低了肝脏移植后的免疫抑制负担,并提高了先发制人抗病毒治疗的可持续性和疗效。因此,在我们的工作中,我们研究了PUVA结合免疫抑制药物(IDs)对体外人DC产生和成熟的体外作用,以有助于理解这种药理学组合的免疫机制。通过使用我们先前描述的体外实验方案,进行单核细胞PUVA处理。在IL-4和GM-CSF存在的情况下,将PUVA处理或未经处理的高度纯化的CD14 +细胞与免疫抑制药物联合孵育,以两种不同的浓度用于肝移植的管理。单独或与PUVA联合使用最高浓度ID(对应于临床实践中的ID)的治疗通过削弱DC的产生和成熟来诱导免疫抑制作用。最低浓度的免疫抑制药物或与PUVA的组合都不会影响髓系DC的产生,但会改变DC的功能,从而增强对致耐受性模式的诱导。由于此ID浓度是任意选择的,因此进一步的实验可能会突出表明,低于临床实践中使用的浓度是否会对DC产生相同的作用并可能改善其功能特性。这项工作描述了一种原始的实验方法,探讨了PUVA与免疫抑制药物联合程序(用于肝移植)对DC生成和功能的体外作用机理。我们的结果有助于了解这种联合程序对DC的作用机理,对体内治疗具有有益的治疗意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号